10/13/2022
APPYEA has been approved for an up-listing to the OTCQB.
Uplisting requires the company to become a quarterly reporter, increasing investor transparency.
Gan Yavne, Israel AppYea (OTC: APYP), a Company focused on developing accurate wearable monitoring solutions to treat sleep apnea and snoring, is pleased to announce that it has been approved by OTC Markets to up list from the OTC PINK to the OTCQB tier. AppYea will trade on the OTCQB exchange under its current symbol "APYP".
Read more on OTCMARKETS...
09/15/2022
Signed an agreement with a hardware manufacturer of its DreamIT wristband.
First stock is expected to arrive during November.
09/08/2022
AppYea Inc. (OTC: APYP) received extention confirmation for strategic patent in UK, Germany and France.
The patent protects the rights to use a microphone of any type and sound analysis for the purpose of identifying and diagnosing sleep apnea.
Read more on OTCMARKETS ...
09/07/2022
Tell us about yourself?
45 years old, married + 2. Master’s degree in business administration with a specialization in finance and capital markets. I believe that any dream can be realized through perseverance and determination.
What lessons has being an entrepreneur taught you?
To be successful you have to work hard. The more you do, the more likely you are to make mistakes. You must not be afraid of mistakes, but you must not repeat them.
If you could go back in time to when you first started your business, what piece of advice would you give yourself?
In an R&D company, it is impossible to achieve a perfect product, so you have to strive to develop a very good product. start marketing and in parallel constantly continue to develop and improve the product and add new features.
Don’t expect quick results. Use patience and perseverance.
Continue reading on https://beststartuptexas.com/
09/07/2022
Received an extension of GERMANY patent - APPARATUS AND METHOD FOR DIAGNOSING OBSTRUCTIVE SLEEP APNEA No. 60 2011 026 579.2
09/06/2022
Received an extension of UK patent - APPARATUS AND METHOD FOR DIAGNOSING OBSTRUCTIVE SLEEP APNEA No. EP2608717
08/29/2022
08/04/2022
AppYea were selected as a top startup in Texas:
101 Texas, United States Based Android Companies | The Most Innovative Android Companies
At Best Startup Texas we track over 100,000 Texan startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and organisations we think deserve more appreciation than they are currently getting.
Read more on best startup texas...
07/07/2022
First version of the SleepX APP has been uploaded to the Google Play Store.
The app is available for free download for all versions of Android starting with version 7.0.
Without a wristband, the current version can be used for breath monitoring, snoring detection and intensity, as well as the amount of snoring per sleep session. The app also provides the user a breathing graph as well as a recording each sleep session. Read more on Yahoo finance...
06/23/2022
Undervalued health-tech small-cap in the billion-dollar sleep apnea market (OTC: APYP)
SleepX, an AppYea (OTC: APYP) subsidiary, is a health-tech company focused on developing accurate wearable monitoring solutions to treat sleep apnea and snoring and fundamentally improve quality of life.
Read more on reddit...
05/31/2022
SleepX approved by the Helsinki Committee to conduct clinical trial with the SleepX PRO smartphone application.
leepX PRO is designed to diagnose sleep apnea using only a smartphone, with no physical contact. The trial will be conducted at Soroka Hospital in Be'er Sheva, Israel and will include up to 150 subjects.
Read more on Yahoo finance...
05/16/2022
Global Smart Sleep Tracking Products Market to Garner a Revenue of USD 11,234.55 Million by 2028 and Grow with a CAGR of 17.50% during 2020-2028; Surge in Concern for Sleep-Related Disorders to Drive the Market Growth.
Read more on Yahoo finance...
05/16/2022
Gan Yavne, Israel; AppYea (OTC: APYP)
AppYea expands its SleepX patent commercialization portfolio with a non-diluting agreement.
SleepX signed a new commercialization agreement for two new patents. The SleepX PRO solution is designed to diagnose sleep apnea using only a smartphone, with no physical contact.
Read more on Yahoo finance...
05/12/2022
Gan Yavne, Israel; AppYea (OTC: APYP)
Todd Violet has resigned as the company's director and CEO and shall be replaced by Bary Molchadsky, the company's chairman.
05/11/2022
Gan Yavne, Israel; AppYea (OTC: APYP)
AppYea files consolidated 2020 and 2021audited financial statements.
AppYea, which through its wholly owned subsidiary SleepX, is focused on the development of accurate wearable monitoring solutions to monitor and treat sleep apnea and snoring, is pleased to announce the filing of a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC).
Read more on OTC Markets...
05/05/2022
Boca Raton, Florida; AppYea (OTC: APYP)
Symbol was changed back to APYP
04/27/2022
Boca Raton, Florida; AppYea (OTC: APYPD)
Appyea to expand its patent portfolio, on a non-dilutive transaction.
SleepX (AppYea's subsidiary) is in advanced negotiations to sign an exclusive license agreement to commercialize 2 additional US patents in the field of monitoring and diagnosis of sleep apnea through speech analysis.
04/20/2022
Boca Raton, Florida; AppYea (OTC: APYPD)
The Company reducing its authorized shares by 91% from 10 billion to 900 million.
04/14/2022
Boca Raton, Florida; AppYea (OTC: APYPD)
We have completed the development of our application for treatment of snoring.
04/06/2022
Boca Raton, Florida; AppYea (OTC: APYPD)
Company presentation
03/31/2022
Boca Raton, Florida; AppYea (OTC: APYPD)
Annual report for the period ended 12/31/2021.
03/23/2022
Boca Raton, Florida; AppYea (OTC: APYPD)
SleepX applies to the Helsinki Committee for approval on its clinical trial with the SleepX PRO smartphone application.
SleepX PRO is designed to diagnose sleep apnea using only a smartphone, and with no physical contact. Continue reading on yahoo finance...
03/21/2022
Dear investors, due to the RS made, the symbol of the stock was changed to APYPD for three weeks. After that, it will return to be APYP again.
Keep track of our announcements as we continue to move forward.
03/14/2022
Boca Raton, Florida; AppYea (OTC:APYPD)
SleepX completes the Beta stage of its wearable data-driven wristband ‘DreamIT’ to treat snoring. Continue reading...
02/08/2022
Boca Raton, Florida; AppYea (OTC:APYP)
We are proud to announce that Neil Kline, founder and former CEO of the American Sleep Association (ASA), joined the board of directors of AppYea.
01/11/2022
Boca Raton, Florida; AppYea (OTC: APYP)
Biomedical AI entrepreneur Prof. Amir Geva appointed CSO of SleepX.
World renowned machine learning and bio-feedback expert joins company to execute and lead the development of DreamIT – the company’s patented solution integrating its proprietary AI technology in a wearable data driven wristband to treat sleep apnea and snoring.
12/31/2021
Boca Raton, Florida; AppYea (OTC: APYP)
AppYea completes acquisition of SleepX, entering a $6-9 billion sleep treatments market: expects to begin marketing during 2H2022
11/16/2021
AppYea takes steps for Future Growth
09/23/2021
09/17/2021
Israeli SleepX to be merged into AppYea Inc. (APYP)
A revolutionary AI approach to the problem of snoring
09/08/2021
Nevada, Sept 8, 2021. AppYea continues the process of merging SleepX into the company. The merger is expected to be completed by 12/01/2021 in accordance with the model published on 08/02/2021.
09/02/2021
09/02/2021
Following the update on 02/23/2021, a final payment was made to the University as part of a patent rights license agreement.
08/19/2021
08/12/2021
Filed on August 10, 2021: Reply to exam report IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
For: APPARATUS AND METHOD FOR DIAGNOSING SLEEP QUALITY
Appl. No. 14/404,621
Filed: 11/30/2014
08/02/2021
APYP Merger News:
AppYea, Inc. and SleepX Ltd. Agree to Securities Exchange Agreement.
New York, NY, August 02, 2021 (GLOBE NEWSWIRE) -- AppYea, Inc. (OTCPINK: APYP) announced today that it has entered into a Securities Exchange Agreement with SleepX Ltd., an Israeli company ("SleepX") and the shareholders of SleepX pursuant to which SleepX would become a wholly-owned subsidiary of APYP, and the shareholders of SleepX would receive such number of shares of common stock of APYP as described below. Continue reading...
07/17/2021
INSIDER FINANCIAL - OTC STOCKS TO WATCH #1 APYP
AppYea, Inc has been correcting during the last five days, but the OTC stock is on track to become a major winner in the coming months. The share price fell 44% to $0.0041 and is likely to find strong support at $0.0037. The price hit $0.0077 on July 9, getting close to February’s one cent, which remains the highest level year-to-date (YTD) and since 2015. Still, the long-term bull run is only making its first steps.
07/01/2021
03/21/2021
The global sleep apnea devices market size was valued at USD 3.7 billion in 2020 and is expected to expand at a compound annual growth rate of 6.2% from 2021 to 2028. Sleep apnea is a sleeping disorder, characterized by irregular breathing, thus providing insufficient oxygen to the brain. According to an American Sleep Association study published in 2020, an estimated 50 million to 70 million people in the U.S. are suffering from some form of sleep disorders. Moreover, according to Canadian Respiratory Journal in 2014, around 5.4 million adults in Canada were diagnosed with sleep apnea or were at higher risk of developing OSA. According to a study conducted by ResMed in 2018, around 175 million people in Europe were suffering from sleep apnea. Continue reading...
02/23/2021
Paid 60% of the payment for the University's Patent License Agreement.
Examines an engagement with a leading law firm specializing in patent litigation and intellectual property protection. Vew our IP portfolio
02/18/2021
01/31/2021
Following the public disclosure of the LOI amongst our companies and APPYA Inc. (OTCPINK: APYP),
we are pleased to announce that we have reached preliminary understandings on the principal terms of the acquisition and are working towards it.
We believe that the acquisition should provide significant value for all parties and allow the DreamIT X3, our principal anti-snoring product, to reach the market as early as the first half of 2022 under the “Wellness Gadgets” category, which will allow for a shorter time for the market.
We believe that there is a pressing need for the device. According to the American National Sleep Foundation in the United States, 57% of men and 40% of women suffer from chronic snoring https://www.sleepfoundation.org/snoring
DreamIT X3 is based on a unique technology that is patents protected and is a revolutionary solution to snoring. We believe the unit retael price should not exced $149.
We are excited to begin working with our US strategic partners to realize our business vision!
